FIT Stack Review: CJC-1295 + Ipamorelin Growth Hormone Stack (2026)

Quick Take: The FIT Stack from Ascension Peptides pairs CJC-1295 no DAC with Ipamorelin at $100 — the gold-standard GH secretagogue combination in research. These two peptides work through complementary pathways to produce synergistic growth hormone release that neither achieves alone. If you're studying GH optimization, body composition, or sleep architecture, this is the stack.

CJC-1295 + Ipamorelin is the most researched GH secretagogue combination in the peptide space. The pairing has become the default protocol for GH axis research because the two compounds hit different receptors — GHRH and GHRP pathways respectively — producing a synergistic GH pulse that is both larger and more selective than either compound generates independently.

Ascension Peptides offers this combination as their FIT Stack at $100. This review covers what's in it, why the combination works, how to research with it, and whether $100 is the right price.

What's in the FIT Stack?

• CJC-1295 no DAC (5mg) — a GHRH analog that stimulates growth hormone-releasing hormone receptors in the pituitary, triggering GH secretion
• Ipamorelin (5mg) — a selective GHRP (growth hormone releasing peptide) that activates ghrelin receptors for targeted GH pulse stimulation

Both arrive as lyophilized powder with Ascension's standard third-party COA documentation (≥98% HPLC purity). You'll need bacteriostatic water for reconstitution — stocks this separately for $14–$15.

CJC-1295 No DAC: The GHRH Analog

CJC-1295 without DAC (also called Modified GRF 1-29) is a truncated, stabilized analog of growth hormone-releasing hormone (GHRH). It binds to GHRH receptors in the pituitary gland and stimulates the release of endogenous growth hormone — not exogenous GH administration, but activation of the body's own GH production mechanism.

The "no DAC" designation means it lacks the Drug Affinity Complex that extends the half-life of the DAC version to several days. Without DAC, CJC-1295 has a half-life of approximately 30 minutes — shorter, but this actually better mimics natural pulsatile GH secretion patterns. For research studying the physiological GH rhythm, the no-DAC version is the more appropriate compound.

A landmark study published in the Journal of Clinical Endocrinology & Metabolism found CJC-1295 (with DAC) increased GH levels 2–10× above baseline and sustained elevated IGF-1 for up to 6 days post-injection. The no-DAC version produces a more acute, pronounced peak that researchers can time to specific physiological windows — typically pre-sleep when natural GH secretion is highest.

Typical research dosing: 100–200 mcg per injection, 1–3× daily, with at least one injection timed 30–60 minutes before sleep.

Ipamorelin: The Selective GHRP

Ipamorelin is a pentapeptide GH secretagogue that works through a completely different mechanism than CJC-1295. Where CJC-1295 acts on GHRH receptors, Ipamorelin activates ghrelin receptors (specifically GHS-R1a) to trigger GH release from somatotroph cells. This dual-pathway activation is why the combination is synergistic — you're stimulating two independent GH release mechanisms simultaneously.

Ipamorelin's key advantage over older GHRPs like GHRP-6 or GHRP-2 is its selectivity. It produces a clean GH pulse without significantly elevating cortisol, prolactin, or ACTH — side effects that complicate interpretation in research using less selective GHRPs. This makes it the preferred GHRP for most research protocols where clean mechanistic data matters.

Typical research dosing: 100–200 mcg per injection, 2–3× daily, timed with CJC-1295 for synergistic pulses.

Why the Combination Is Synergistic

The CJC-1295 + Ipamorelin combination produces GH release greater than the sum of its parts. The mechanism is well established: GHRH analogs (CJC-1295) increase the number of somatotroph cells that respond to a GHRP signal, while GHRPs (Ipamorelin) amplify the magnitude of the GH pulse from each responding cell. Used together, you get more cells releasing more GH per pulse.

Research protocols using both compounds consistently show IGF-1 elevation approximately 20–30% higher than either compound alone at equivalent doses — a meaningful advantage for studies where GH axis activation is the primary endpoint.

Expected Research Outcomes by Timeline

• Week 1–2: Sleep quality improvements (deeper sleep stages, more vivid dreams in sleep architecture studies); possible mild water retention
• Week 3–4: Recovery rate improvements; increased IGF-1 levels detectable in bloodwork
• Week 6–8: Measurable body composition changes in sustained protocols — lean mass increases, fat mass reduction, particularly visceral fat
• Week 12–16: Full body composition effects apparent; skin quality, joint recovery improvements documented in longer-term research

Standard Research Protocol

• Dose: 100–200 mcg CJC-1295 + 100–200 mcg Ipamorelin per injection
• Frequency: 2–3× daily — ideally morning (fasted), post-workout, and pre-sleep
• Minimum effective: 2× daily (morning + pre-sleep) if 3× is not feasible
• Cycle length: 12–16 weeks on, followed by 4–8 weeks off
• Reconstitution: Add 2mL bacteriostatic water per vial; refrigerate; use within 28–30 days

FIT Stack Value vs. Buying Separately

sells CJC-1295 no DAC (5mg) at $50 and Ipamorelin (5mg) at $44 individually. That's $94 separately versus $100 for the FIT Stack. The small premium may include larger quantities or consolidated packaging — check the product page for exact contents. Either way, the price is competitive with the market and the documentation quality justifies it.

Who Is the FIT Stack For?

• GH axis and pituitary function research
• Body composition studies (fat loss + lean mass preservation)
• Sleep architecture research (GH is primarily secreted during deep sleep)
• Anti-aging metabolic research (GH declines ~14% per decade after age 30)
• Recovery and injury healing protocols where GH elevation is a key variable

FAQ

CJC-1295 with DAC vs. no DAC — which is better?

No DAC produces pulsatile GH release that more closely mimics natural physiology. DAC extends the half-life but creates continuous, sustained GH elevation rather than pulses. For most research studying physiological GH patterns, no DAC is preferred. For studies focused purely on IGF-1 elevation maintenance, DAC may be appropriate. The FIT Stack uses no DAC, which is the research community's preferred version.

How is Ipamorelin different from GHRP-6?

Both are GHRPs, but Ipamorelin is far more selective. GHRP-6 significantly elevates cortisol and prolactin alongside GH — which confounds research and causes side effects like intense hunger. Ipamorelin's GH release is clean: minimal cortisol, minimal prolactin, no significant appetite spike. For research where you want to study GH effects without confounding stress hormone elevation, Ipamorelin is the appropriate choice.

Can the FIT Stack be used with other peptides?

Yes. Common additions in research include BPC-157 (for recovery synergy), MK-677 (for sustained GH elevation between injection windows), and Epithalon (for longevity/telomere research). GLP-1 compounds like retatrutide are typically run as separate protocols rather than stacked with GH secretagogues.

→ Get the FIT Stack: Ascension Peptides — CJC-1295 + Ipamorelin bundled with third-party COA verification.

This content is for informational and educational purposes only. CJC-1295 and Ipamorelin are research compounds not approved by the FDA for human therapeutic use. Dosing information is derived from published preclinical and clinical research. PeptideDeck may earn a commission from purchases through affiliate links at no additional cost to you.